BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 23222202)

  • 21. Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia.
    Liu SG; Gao C; Zhang RD; Zhao XX; Cui L; Li WJ; Chen ZP; Yue ZX; Zhang YY; Wu MY; Wang JX; Li ZG; Zheng HY
    Oncotarget; 2017 Jun; 8(23):37761-37772. PubMed ID: 28525903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
    Joannon P; Oviedo I; Campbell M; Tordecilla J
    Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between reduced folate carrier G80A polymorphism and methotrexate toxicity in childhood acute lymphoblastic leukemia: a meta-analysis.
    He HR; Liu P; He GH; Dong WH; Wang MY; Dong YL; Lu J
    Leuk Lymphoma; 2014 Dec; 55(12):2793-800. PubMed ID: 24597986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of SLCO1B1 521T > C variant on leucovorin rescue and risk of relapse in childhood acute lymphoblastic leukemia treated with high-dose methotrexate.
    Zhang HN; He XL; Wang C; Wang Y; Chen YJ; Li JX; Niu CH; Gao P
    Pediatr Blood Cancer; 2014 Dec; 61(12):2203-7. PubMed ID: 25130190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia.
    Salazar J; Altés A; del Río E; Estella J; Rives S; Tasso M; Navajas A; Molina J; Villa M; Vivanco JL; Torrent M; Baiget M; Badell I
    Pharmacogenomics J; 2012 Oct; 12(5):379-85. PubMed ID: 21747412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of plasma methotrexate level and MTHFR genotype in Korean paediatric patients with acute lymphoblastic leukaemia.
    Chae H; Kim M; Choi SH; Kim SK; Lee JW; Chung NG; Cho B; Kim Y
    J Chemother; 2020 Sep; 32(5):251-259. PubMed ID: 32431230
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacogenomic Markers of Methotrexate Response in the Consolidation Phase of Pediatric Acute Lymphoblastic Leukemia Treatment.
    Kotur N; Lazic J; Ristivojevic B; Stankovic B; Gasic V; Dokmanovic L; Krstovski N; Milosevic G; Janic D; Zukic B; Pavlovic S
    Genes (Basel); 2020 Apr; 11(4):. PubMed ID: 32344632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Influence of thymidylate synthase gene polymorphisms on high-dose methotrexate-related toxicities in childhood acute lymphoblastic leukemia].
    Zhu XJ; He XL; Wu YP; Zou RY; Li WL; Zou H; You YL; Liu H; Tian X
    Zhongguo Dang Dai Er Ke Za Zhi; 2015 Jan; 17(1):11-4. PubMed ID: 25616285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High dose methotrexate treatment in childhood ALL: pilot study on the impact of the MTHFR 677C>T and 1298A>C polymorphisms on MTX-related toxicity.
    Haase R; Elsner K; Merkel N; Stiefel M; Mauz-Körholz C; Kramm CM; Körholz D
    Klin Padiatr; 2012 Apr; 224(3):156-9. PubMed ID: 22513795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of methylene tetrahydrofolate reductase polymorphisms and coadministration of antimetabolites on toxicity after high dose methotrexate.
    van Kooten Niekerk PB; Schmiegelow K; Schroeder H
    Eur J Haematol; 2008 Nov; 81(5):391-8. PubMed ID: 18691257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia.
    Aplenc R; Thompson J; Han P; La M; Zhao H; Lange B; Rebbeck T
    Cancer Res; 2005 Mar; 65(6):2482-7. PubMed ID: 15781665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of ABCC2 -24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia.
    Liu Y; Yin Y; Sheng Q; Lu X; Wang F; Lin Z; Tian H; Xu A; Zhang J
    PLoS One; 2014; 9(1):e82681. PubMed ID: 24404132
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial.
    Lui G; Treluyer JM; Fresneau B; Piperno-Neumann S; Gaspar N; Corradini N; Gentet JC; Marec Berard P; Laurence V; Schneider P; Entz-Werle N; Pacquement H; Millot F; Taque S; Freycon C; Lervat C; Le Deley MC; Mahier Ait Oukhatar C; Brugieres L; Le Teuff G; Bouazza N;
    J Clin Pharmacol; 2018 Dec; 58(12):1541-1549. PubMed ID: 29791011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of -24CT, 1249GA, and 3972CT ABCC2 gene polymorphisms with methotrexate serum levels and toxic side effects in children with acute lymphoblastic leukemia.
    Sharifi MJ; Bahoush G; Zaker F; Ansari S; Rafsanjani KA; Sharafi H
    Pediatr Hematol Oncol; 2014 Mar; 31(2):169-77. PubMed ID: 24552501
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between MTHFR microRNA binding site polymorphisms and methotrexate concentrations in Chinese pediatric patients with acute lymphoblastic leukemia.
    Wang SM; Zeng WX; Wu WS; Sun LL; Yan D
    J Gene Med; 2017 Nov; 19(11):353-359. PubMed ID: 28990296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients.
    Lima A; Bernardes M; Azevedo R; Monteiro J; Sousa H; Medeiros R; Seabra V
    Toxicol Sci; 2014 Nov; 142(1):196-209. PubMed ID: 25124723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacogenetic analysis of high-dose methotrexate treatment in children with osteosarcoma.
    Hegyi M; Arany A; Semsei AF; Csordas K; Eipel O; Gezsi A; Kutszegi N; Csoka M; Muller J; Erdelyi DJ; Antal P; Szalai C; Kovacs GT
    Oncotarget; 2017 Feb; 8(6):9388-9398. PubMed ID: 27566582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The miR-1206 microRNA variant is associated with methotrexate-induced oral mucositis in pediatric acute lymphoblastic leukemia.
    Gutierrez-Camino A; Oosterom N; den Hoed MAH; Lopez-Lopez E; Martin-Guerrero I; Pluijm SMF; Pieters R; de Jonge R; Tissing WJE; Heil SG; García-Orad A; van den Heuvel-Eibrink MM
    Pharmacogenet Genomics; 2017 Aug; 27(8):303-306. PubMed ID: 28628559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Methotrexate-induced interstitial pneumonitis in a child with acute lymphoblastic leukemia].
    Tatsumoto C; Kawakami K; Nagayama J; Kawano H
    Rinsho Ketsueki; 2004 Oct; 45(10):1100-4. PubMed ID: 15553044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SLCO1B1 Polymorphisms are Associated With Drug Intolerance in Childhood Leukemia Maintenance Therapy.
    Eldem İ; Yavuz D; Cumaoğullari Ö; İleri T; Ünal İnce E; Ertem M; Doğanay Erdoğan B; Bindak R; Özdağ H; Şatiroğlu-Tufan NL; Uysal LZ
    J Pediatr Hematol Oncol; 2018 Jul; 40(5):e289-e294. PubMed ID: 29683944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.